2023 World Conference on Lung Cancer (Posters)-P2.31. Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution

P2.31. Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the survival outcomes of young patients with non-small cell lung cancer (NSCLC) at a large academic institution. The researchers examined the clinical characteristics of 58 NSCLC patients aged 50 and younger, including age at diagnosis, sex, smoking history, racial/ethnic background, stage at diagnosis, and prevalence of targetable mutations. They performed Kaplan-Meier analysis to determine overall survival (OS) from the time of diagnosis of Stage IV NSCLC to death/last contact, and conducted multivariate Cox regression analysis to evaluate mortality risk.<br /><br />The results showed that the median age at diagnosis was 45 years, with 60% female patients. The majority of patients identified as never smokers. Adenocarcinoma was the most common histopathology, and 75.9% of patients presented with Stage IV disease at diagnosis. The most common sites of metastasis were bone and brain. Targetable mutations were found in 71.1% of Stage IV patients, with ALK and EGFR mutations being the most prevalent. The median OS for metastatic patients was 50.01 months.<br /><br />The study also found that Hispanics had a worse median OS compared to Asians and non-Hispanic whites. However, patients with targetable mutations who were exposed to a tyrosine kinase inhibitor (TKI) had significantly greater OS than those without targetable mutations. When controlling for various factors, Hispanic ethnicity was found to be a significant risk factor for OS, but this risk was mitigated when considering TKI exposure.<br /><br />In conclusion, young NSCLC patients with a targetable mutation who were treated with TKI had a prolonged median survival. The use of liquid biopsy increased the chance of identifying these mutations. While Hispanic patients had an increased mortality risk overall, this risk was reduced with TKI treatment.

Asset Subtitle

Robert Hsu

Meta Tag

Speaker Robert Hsu

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

survival outcomes

young patients

NSCLC

clinical characteristics

targetable mutations

overall survival

Stage IV NSCLC

mortality risk

median age at diagnosis

TKI treatment